Abstract
Here we have studied the effects of apoptotic cell death induced by chemotherapic agents on tumor phagocytosis by dendritic cells (DC) and presentation of the relevant antigen to T lymphocytes. Annexin-V-FITC (Ann-V) and propidium iodide (PI) staining was used to assess early apoptotic (Ann-V(+)/PI(-)) vs. late apoptotic/secondary necrotic (Ann-V(+)/PI(+)) death after a 24 hr observation of untreated and drug-treated gastric carcinoma cells. After treatments, the HLA-A*0201(+) tumor cell line KATO III was exposed for 24 hr to allogeneic, HLA-related GM-CSF, IL-4-driven immature (i) DC. Tumor-loaded iDC were tested for IL-12 release in an ELISA assay, incubated with the DC-maturating factor TNF-alpha and used as stimulators for autologous T lymphocytes. Generation of antitumor T response against KATO cells was evaluated in an anti-MHC class I MAb-blocked Interferon-gamma ELISPOT assay. After treatment with Cis-platin (cis), all dying cells were in early apoptosis, whereas secondary necrosis was the prevalent death pattern observed after epirubicin (epi) and doxorubicin (doxo). Doxo and epi increased tumor expression of heat shock protein (hsp) 70 and uptake of tumor cell components by DC, whereas cis treatment had no effect on hsp70 and was associated with poor tumor uptake by DC. Significant upmodulation of IL-12 was observed by DC that had taken up the doxo- and epi-treated tumors (p< 0.005 and p< 0.01, respectively). Increased IFN-gamma release was also observed after stimulation of T lymphocytes with DC loaded with doxo- and epi-treated (p< 0.02 and p< 0.005, respectively) but not with cis-treated DC. These data show that the products of early apoptosis cannot efficiently cross-activate MHC class I-restricted anti-tumor lymphocytes even in the presence of DC maturating factors, whereas secondary necrosis is associated with robust T cell response.
MeSH Terms
Annexin A5/metabolism
Antigen Presentation/physiology
Antigens, Neoplasm/immunology
Antineoplastic Agents/pharmacology
Apoptosis/drug effects
Cisplatin/pharmacology
Cytokines/metabolism
Dendritic Cells/immunology
Doxorubicin/pharmacology
Epirubicin/pharmacology
HSP70 Heat-Shock Proteins/metabolism
Histocompatibility Antigens Class I/immunology
Humans
Necrosis
Phagocytosis/drug effects
Propidium/metabolism
Stomach Neoplasms/pathology
T-Lymphocytes, Cytotoxic/immunology
Tumor Cells, Cultured
Chemicals
Annexin A5
Antigens, Neoplasm
Antineoplastic Agents
Cytokines
HSP70 Heat-Shock Proteins
Histocompatibility Antigens Class I
Propidium
Epirubicin
Doxorubicin
Cisplatin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Buttiglieri Stefano
Department of Oncology, Centro OncoEmatologicoSubalpino (COES), Turin, Italy.
Galetto Alessandra
Department of Oncology, Centro OncoEmatologicoSubalpino (COES), Turin, Italy.
Forno Sarah
Department of Internal Medicine, University of Turin, Turin, Italy.
De Andrea Marco
Department of Microbiology and Public Health, Turin, Italy.
Matera Lina
Department of Internal Medicine, University of Turin, Turin, Italy.
References (35)
35 references, click to expand
-
Boom T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997; 9: 681-3.
-
Wang RF. Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999; 170: 85-00.
-
Foon KA. Immunotherapy for colorectal cancer. Curr Oncol Rep 2001; 3: 16-26.
-
Hanna MG Jr, Hoover HC Jr, Vermorken JB. Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001; 19: 2576-82.
-
Banchereau J. Steinman R. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
-
Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-8.
-
Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92: 8078-82.
-
Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
-
Lodge PA, Lori AJ, Bader RA, Murphy GB, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829-33.
-
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T cell epitopes derived from MUC-1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309-18.
-
Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-68.
-
Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune response. J Immunol 2000; 165: 3797-803.
-
Rovere, P, Vallinoto, C, Bondanza, A, Crosti, M. C, Rescigno, M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467-71.
-
Russo V, Tanzarella S, Dalerba P. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad 2000; 97: 2185-90.
-
Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999; 59: 3329-32.
-
Galetto A, Contarini M, Sapino A, Cassoni P, Consalvo E, Forno S, Pezzi C, Barnaba V, Mussa A, Matera L. Ex-vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells. J Surgical Res 2001; 100: 32-8.
-
Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191: 795-804.
-
Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22: 141-8.
-
Voll RE, Hermann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-1.
-
Kotera, Y, Shimizu K, Mulé JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigens in dendritic cell-based immunization. Cancer Res 2001; 61: 8105-9.
-
Sauter B, Albert M, Francisco L, Larsson M, Somersan S, Bhardwaj L. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-34.
-
Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000; 60: 3542-9.
-
Basu S, Binder R, Suto R, Anderson K, Srivastava P. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NK-κB pathway. Int Immunol 2000; 12: 1539-46.
-
Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med, 1999; 5: 1249-55.
-
Bausinger H, Lipsker D, Hanau D. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23: 342-3.
-
Pietra G, Mortarini R, Parmiani G, Anichini A. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res 2001; 61: 8218-26.
-
Sekiguchi M, Sakakibara K, Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 1978; 48: 61-8.
-
Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993; 32: 379-84.
-
Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 1993; 32: 53-8.
-
Bunz F. Cell death and cancer therapy. Curr Opin Pharmacol 2001; 1: 337-41.
-
Herr W, Linn B, Leister N, Wandel E, Meyer Zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997; 203: 141-52.
-
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 1998; 101: 890-8.
-
Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-8.
-
Strasser A, Dr. Josef Steiner Cancer Research Prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int J Cancer 1999; 81: 505-11.
-
Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol 1999; 163: 1730-2.